Merriman Curhan Ford reiterates a 'Buy' on Celldex Therapeutics, Inc. (Nasdaq: CLDX), raises target range.

Merriman analyst says, "Celldex is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE